AOD9604: A Metabolic Research Overview
All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone (hGH) and is frequently referenced in laboratory studies of fat metabolism. All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice. This overview summarizes how researchers have characterized the molecule and the boundaries of the current evidence base.
What AOD9604 Is
AOD9604 (sometimes written AOD-9604) is a modified fragment derived from the final amino acids of the human growth hormone molecule, with the designation "AOD" referring to its description as an anti-obesity drug candidate in early literature. Rather than reproducing the full hormone, the peptide isolates a short C-terminal sequence that researchers associated with lipid-related activity. In published research it has been studied as a tool for examining how discrete portions of a larger hormone can exhibit activity distinct from the parent molecule. For background on how research peptides are prepared in the laboratory, see our notes on reconstituting peptides.
Mechanism: What the Research Explores
A central question in AOD9604 research has been whether the fragment acts through the same pathways as full-length growth hormone. According to PubMed-indexed work, studies have examined the peptide's relationship to fat oxidation and lipolysis in animal models. Researchers reported that, in obese mouse models, the fragment was associated with reduced body weight gain and increased markers of fat breakdown, while data indicated it did not compete for the growth hormone receptor in the assays used. Other studies have examined its interaction with the beta-3 adrenergic pathway, a receptor system involved in fat-cell signaling, reporting changes in receptor expression rather than direct receptor binding. These findings describe observations in laboratory models and do not establish effects in humans.
Research Stage and Limitations
Much of the foundational AOD9604 literature originates from animal and in vitro work conducted in the early 2000s, with later review articles listing it among investigational metabolic compounds. It is important to emphasize that the bulk of mechanistic data comes from rodent models and cell assays, which do not reliably translate to human outcomes. The compound is not an approved therapeutic, and BioRegen presents this material strictly as a summary of the scientific record for research and educational reference. Community and forum discussions about the peptide exist online, but any such material should be regarded as unverified anecdotal reports, not controlled findings, and BioRegen does not make or endorse any claims based on them. Researchers comparing metabolic research compounds may also find our comparison of retatrutide, tirzepatide, and semaglutide useful for context.
Handling Notes for the Laboratory
As with most lyophilized research peptides, published handling practice describes storing the dry powder cold and protected from light, and preparing working solutions only with appropriate laboratory diluents. Reconstituted material is generally treated as less stable than the lyophilized form. These are general handling observations described in peptide research literature and are provided for laboratory reference only, not as a usage protocol. To locate related research compounds, the research finder can help narrow a search by category.
Frequently Asked Questions
Is AOD9604 the same as human growth hormone?
No. In published research AOD9604 is described as a short fragment based on the C-terminal region of human growth hormone, not the complete hormone. Studies reported that it did not compete for the growth hormone receptor in the assays used, which is why researchers have studied it as a distinct molecule.
What have studies focused on?
Much of the literature has examined fat oxidation, lipolysis, and related metabolic markers in animal models, along with the peptide's relationship to adrenergic signaling pathways. These are laboratory observations, not demonstrated human outcomes.
Is AOD9604 approved for use?
No compound referenced on this page is approved for human or veterinary use. AOD9604 is referenced here solely as a subject of laboratory and educational research.
Selected Research References
- Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001. https://doi.org/10.1038/sj.ijo.0801740
- Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001. https://doi.org/10.1210/endo.142.12.8522
Reference metadata sourced via PubMed.
Planning a research project around metabolic peptides? Explore our research guide for laboratory background, and use code RESEARCH10 for 10% off your first order. You can browse related compounds in our metabolic research category.
This content is provided strictly for laboratory and educational research purposes. No compound referenced is approved for human or veterinary use, and nothing here constitutes medical advice or a recommendation for use in humans or animals. BioRegen makes no therapeutic claims of any kind.